{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:47Z","timestamp":1787004827557,"version":"build-2736575974"},"reference-count":184,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1053\/j.seminhematol.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T13:04:12Z","timestamp":1595855052000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease"],"prefix":"10.1053","volume":"57","author":[{"given":"Prajeeda M.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Rendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-9780","authenticated-orcid":false,"given":"Kristin M.","family":"Reddoch-Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9958-9115","authenticated-orcid":false,"given":"Michael A.","family":"Meledeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Cap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2020.07.006_bib0001","unstructured":"American Association of Blood Banks (AABB). Circular of information for the use of human blood and blood components. 2017."},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0002","series-title":"Pooled plasma (human), solvent\/detergent treated solution for intravenous infusion","year":"2013"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2020.07.006_bib0003","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(02)00146-9","article-title":"Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases","volume":"107","author":"Mueller","year":"2002","journal-title":"Thromb Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/MAJ.0000000000000403","article-title":"Endothelial dysfunction in advanced liver disease","volume":"349","author":"Rockey","year":"2015","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4254\/wjh.v7.i3.443","article-title":"Endothelial dysfunction in cirrhosis: role of inflammation and oxidative stress","volume":"7","author":"Vairappan","year":"2015","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0006","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619852163","article-title":"Endothelial dysfunction is associated with mortality and severity of coagulopathy in patients with sepsis and disseminated intravascular coagulation","volume":"25","author":"Walborn","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0008","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-0038-1642658","article-title":"Tissue factor pathway inhibitor","volume":"74","author":"Broze","year":"1995","journal-title":"Thromb Haemostas"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0009","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1055\/s-0038-1655981","article-title":"Anticoagulant properties of the vascular endothelium","volume":"77","author":"Bombeli","year":"1997","journal-title":"Thromb Haemostas"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2020.07.006_bib0010","first-page":"S182","article-title":"\"Blood failure\" time to view blood as an organ: how oxygen debt contributes to blood failure and its implications for remote damage control resuscitation","volume":"56","author":"Bjerkvig","year":"2016","journal-title":"Transfusion"},{"issue":"6S Suppl 1","key":"10.1053\/j.seminhematol.2020.07.006_bib0011","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/TA.0000000000001436","article-title":"Hemorrhagic blood failure: oxygen debt, coagulopathy, and endothelial damage","volume":"82","author":"White","year":"2017","journal-title":"J Trauma Acute Care Surg"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2020.07.006_bib0012","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/milmed\/usy112","article-title":"Damage control resuscitation","volume":"183","author":"Cap","year":"2018","journal-title":"Military Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0013","first-page":"805","article-title":"The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital","volume":"63","author":"Borgman","year":"2007","journal-title":"J Trauma"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0014","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jama.2015.12","article-title":"Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the proper randomized clinical trial","volume":"313","author":"Holcomb","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jamcollsurg.2010.01.031","article-title":"Impact of plasma transfusion in trauma patients who do not require massive transfusion","volume":"210","author":"Inaba","year":"2010","journal-title":"J Am Coll Surg"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.07.006_bib0016","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMcp025373","article-title":"Clinical practice. Care of patients receiving long-term anticoagulant therapy","volume":"349","author":"Schulman","year":"2003","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.2005.05856.x","article-title":"Guidelines on oral anticoagulation (warfarin): third edition\u20142005 update","volume":"132","author":"Baglin","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0018","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2141.2001.02908.x","article-title":"The management of coumarin-induced over-anticoagulation annotation","volume":"114","author":"Makris","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.2005.00648.x","article-title":"Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion","volume":"89","author":"Bux","year":"2005","journal-title":"Vox Sanguin"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1378\/chest.06-3048","article-title":"Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients","volume":"131","author":"Khan","year":"2007","journal-title":"Chest"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40560-018-0303-y","article-title":"Safety of 4-factor prothrombin complex concentrate (4f-pcc) for emergent reversal of factor xa inhibitors","volume":"6","author":"Tao","year":"2018","journal-title":"J Intensive Care"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0022","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/ALN.0000000000002399","article-title":"Prothrombin complex concentrates for perioperative vitamin k antagonist and non-vitamin k anticoagulant reversal","volume":"129","author":"Levy","year":"2018","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0023","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11239-017-1506-0","article-title":"Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin k antagonist associated bleeding: a systematic review and meta-analysis","volume":"44","author":"Brekelmans","year":"2017","journal-title":"J Thrombos Thrombol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"Guidelines on oral anticoagulation with warfarin \u2013 fourth edition","volume":"154","author":"Keeling","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1655992","article-title":"Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy","volume":"77","author":"Makris","year":"1997","journal-title":"Thromb Haemostas"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0026","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0027","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"Chander","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0028","first-page":"15","article-title":"Management of thrombotic thrombocytopenic purpura: current perspectives","volume":"5","author":"Blombery","year":"2014","journal-title":"J Blood Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2020.07.006_bib0029","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant adamts-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jcp.1040860104","article-title":"Variations in the cell-free translating apparatus of cultured animal cells as a function of time during cell growth","volume":"86","author":"Engelhardt","year":"1975","journal-title":"J Cell Physiol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0031","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/cc8205","article-title":"Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers","volume":"14","author":"Nascimento","year":"2010","journal-title":"Crit Care (Lond, Engl)"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0032","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2019.09.024","article-title":"Nails in the coffin of fresh frozen plasma to prevent or treat bleeding in cirrhosis?","volume":"72","author":"Bernal","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0033","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7861\/clinmedicine.13-2-200","article-title":"Uses and abuses of fresh frozen plasma for the treatment of bleeding","volume":"13","author":"Desborough","year":"2013","journal-title":"Clin Med (Lond, Engl)"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0034","series-title":"Hematology","first-page":"179","article-title":"The evidence-based use of ffp and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy","author":"Stanworth","year":"2007"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2004.04973.x","article-title":"Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials","volume":"126","author":"Stanworth","year":"2004","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.07.006_bib0036","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for Mers-Cov infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0037","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"14","key":"10.1053\/j.seminhematol.2020.07.006_bib0038","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"17","key":"10.1053\/j.seminhematol.2020.07.006_bib0041","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1053\/j.seminhematol.2020.07.006_bib0042","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2020.07.006_sbref0043","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China","author":"Ye","year":"2020","journal-title":"J Med Virol"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0044","unstructured":"US Food and Drug Administration. Investigational COVID-19 convalescent plasma \u2013 emergency inds. 2020. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/recommendations-investigational-covid-19-convalescent-plasma."},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0045","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.07.006_bib0046","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in middle east respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0047","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tmrv.2009.03.001","article-title":"Cryoprecipitate: the current state of knowledge","volume":"23","author":"Callum","year":"2009","journal-title":"Transfus Med Rev"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0048","unstructured":"American Association of Blood Banks (AABB). Circular of information for the use of human blood and blood components. 2013."},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0049","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0970-9185.81849","article-title":"Blood component therapy: which, when and how much","volume":"27","author":"Arya","year":"2011","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0050","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1365-2141.2010.08208.x","article-title":"A critical evaluation of cryoprecipitate for replacement of fibrinogen","volume":"149","author":"S\u00f8rensen","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0051","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/203312a0","article-title":"High-potency antih\u00e6mophilic factor concentrate prepared from cryoglobulin precipitate","volume":"203","author":"Pool","year":"1964","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0052","unstructured":"Prevention Center for Disease Control and PreventionfDCa. Treatment of hemophilia. 2020. Available from: https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/treatment.html"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0053","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1076029615601494","article-title":"Over 50 years of fibrinogen concentrate","volume":"22","author":"Costa-Filho","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0054","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-3148.2012.01181.x","article-title":"Cryoprecipitate: an outmoded treatment?","volume":"22","author":"Yang","year":"2012","journal-title":"Transfus Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1538-7836.2012.04752.x","article-title":"Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes","volume":"10","author":"Rourke","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0056","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/ATVBAHA.117.308564","article-title":"Fibrinogen and fibrin in hemostasis and thrombosis","volume":"37","author":"Kattula","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0057","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.injury.2016.12.012","article-title":"Fibrinogen in traumatic haemorrhage: a narrative review","volume":"48","author":"Winearls","year":"2017","journal-title":"Injury"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0058","doi-asserted-by":"crossref","first-page":"21","DOI":"10.55460\/ZGAF-INZU","article-title":"TCCC guidelines comprehensive review and update: TCCC guidelines change 16-03","volume":"17","author":"Montgomery","year":"2017","journal-title":"J Spec Oper Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0059","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/cc12685","article-title":"Management of bleeding and coagulopathy following major trauma: an updated European guideline","volume":"17","author":"Spahn","year":"2013","journal-title":"Crit Care (Lond, Engl)"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0060","first-page":"S79","article-title":"The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital","volume":"64","author":"Stinger","year":"2008","journal-title":"J Trauma"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0061","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/bja\/aev134","article-title":"Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial","volume":"115","author":"Curry","year":"2015","journal-title":"Br J Anaesth"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0062","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-3148.2012.01178.x","article-title":"The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage\u2014an observational study","volume":"22","author":"Ahmed","year":"2012","journal-title":"Transfus med"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0063","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/jcp.35.6.667","article-title":"Acquired dysfibrinogenaemia in liver disease","volume":"35","author":"Francis","year":"1982","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0064","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/TP.0000000000002092","article-title":"Perioperative coagulation management in liver transplant recipients","volume":"102","author":"Bezinover","year":"2018","journal-title":"Transplantation"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1160\/TH14-07-0629","article-title":"Clinical and molecular characteristics of 21 patients affected by quantitative fibrinogen deficiency","volume":"113","author":"Asselta","year":"2015","journal-title":"Throm Haemost"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0066","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-0029-1225757","article-title":"Rare bleeding disorders: general aspects of clinical features, diagnosis, and management","volume":"35","author":"Peyvandi","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"10.1053\/j.seminhematol.2020.07.006_bib0067","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment","volume":"125","author":"Palla","year":"2015","journal-title":"Blood"},{"issue":"S2","key":"10.1053\/j.seminhematol.2020.07.006_bib0068","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/trf.15180","article-title":"Hemostatic characteristics of thawed, pooled cryoprecipitate stored for 35 days at refrigerated and room temperatures","volume":"59","author":"Fenderson","year":"2019","journal-title":"Transfusion"},{"issue":"3s","key":"10.1053\/j.seminhematol.2020.07.006_bib0069","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0070","unstructured":"US Food and Drug Administration. Information about immune globulin (human) product shortage. 2020; (04.30.20). Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/information-about-immune-globulin-human-product-shortage."},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0071","series-title":"American Society of Hematology self-assessment program","first-page":"350","article-title":"Transfusion medicine","author":"Savage","year":"2019"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0072","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMcibr0803649","article-title":"The antiinflammatory IGG","volume":"359","author":"Kaveri","year":"2008","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0073","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2011.01.002","article-title":"Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+ CD16++ monocytes in common variable immunodeficiency (CVID) patients","volume":"139","author":"Siedlar","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0074","series-title":"[package insert]","year":"2017"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0075","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1537-2995.2006.00792.x","article-title":"Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature","volume":"46","author":"Darabi","year":"2006","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0076","series-title":"(Immune Globulin Intravenous [human], 10% liquid,) [package insert]","year":"2007"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0077","series-title":"10% caprylate\/chromatography purified) [package insert]","year":"2016"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0078","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2015-05-647552","article-title":"Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy","volume":"127","author":"Ammann","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0079","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","article-title":"Case-control study of thromboembolic events associated with iv immunoglobulin","volume":"256","author":"Caress","year":"2009","journal-title":"J Neurol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1423-0410.2011.01502.x","article-title":"Identification of Kallikrein and Fxia as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products","volume":"102","author":"Etscheid","year":"2012","journal-title":"Vox Sanguin"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0081","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/vox.12025","article-title":"Thromboembolic events associated with immunoglobulin treatment","volume":"105","author":"Funk","year":"2013","journal-title":"Vox Sanguin"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0082","series-title":"(Immune Globulin Intravenous [human] 10%) [package insert]","year":"2005"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0083","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.ajkd.2007.10.044","article-title":"Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes","volume":"51","author":"Dickenmann","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0084","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/mus.24942","article-title":"Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease","volume":"53","author":"Lozeron","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.ajkd.2009.06.013","article-title":"Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion","volume":"55","author":"Welles","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.07.006_bib0086","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","article-title":"Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis","volume":"48","author":"Daw","year":"2008","journal-title":"Transfusion"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2020.07.006_bib0087","first-page":"S117","article-title":"Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products","volume":"55","author":"Hoefferer","year":"2015","journal-title":"Transfusion"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0088","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/trf.12939","article-title":"Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment","volume":"55","author":"Quinti","year":"2015","journal-title":"Transfusion"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0089","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10072-010-0352-z","article-title":"Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report","volume":"31","author":"Dacci","year":"2010","journal-title":"Neurol Sci"},{"issue":"9826","key":"10.1053\/j.seminhematol.2020.07.006_bib0090","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","article-title":"Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (raise study): a randomised, open-label, blinded-endpoints trial","volume":"379","author":"Kobayashi","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0091","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0092","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0034-1381232","article-title":"The history of hemophilia","volume":"40","author":"Franchini","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0093","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.transci.2019.08.005","article-title":"Comprehensive care for hemophilia and other inherited bleeding disorders","volume":"58","author":"Page","year":"2019","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.07.006_bib0094","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1089\/hum.2017.116","article-title":"Hemophilia gene therapy: ready for prime time?","volume":"28","author":"VandenDriessche","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2174\/1566523218666180214162312","article-title":"What's new in gene therapy of hemophilia","volume":"18","author":"Rodriguez-Merchan","year":"2018","journal-title":"Curr Gene Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0096","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","article-title":"Gene therapy for hemophilia","volume":"25","author":"Nienhuis","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0097","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.biomaterials.2010.08.094","article-title":"Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia b","volume":"32","author":"Coutu","year":"2011","journal-title":"Biomaterials"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.07.006_bib0098","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.exphem.2011.09.001","article-title":"Phenotypic correction of hemophilia a in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC","volume":"39","author":"Porada","year":"2011","journal-title":"Exp Hematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2020.07.006_bib0099","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.2019000790","article-title":"Crispr\/cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice","volume":"133","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2019.02.009","article-title":"Long-term correction of hemophilia b using adenoviral delivery of CRISPR\/CAS9","volume":"298","author":"Stephens","year":"2019","journal-title":"J Control Release"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0101","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-cell-directed bioengineering approaches for gene therapy of hemophilia a","volume":"9","author":"Brown","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21","key":"10.1053\/j.seminhematol.2020.07.006_bib0102","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia a","volume":"374","author":"Shima","year":"2016","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.07.006_bib0103","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia a without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0104","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia a without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0105","series-title":"Fibrinogen","author":"Kaur","year":"2020"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-0039-1696946","article-title":"Fibrinogen supplementation and its indications","volume":"46","author":"Grottke","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0107","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/VHRM.S5305","article-title":"Treatment of congenital fibrinogen deficiency: overview and recent findings","volume":"5","author":"Tziomalos","year":"2009","journal-title":"Vasc Health Risk Manag"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2020.07.006_bib0108","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0049-3848(09)70159-8","article-title":"Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders?","volume":"124","author":"Bevan","year":"2009","journal-title":"Thromb Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0109","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/vox.12417","article-title":"Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients \u2013 an economic evaluation","volume":"111","author":"Okerberg","year":"2016","journal-title":"Vox Sanguin"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0110","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-3148.2012.01168.x","article-title":"National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia","volume":"22","author":"Gollop","year":"2012","journal-title":"Transfus Med"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0111","doi-asserted-by":"crossref","first-page":"46749","DOI":"10.1038\/srep46749","article-title":"The clinical efficacy of fibrinogen concentrate in massive obstetric haemorrhage with hypofibrinogenaemia","volume":"7","author":"Matsunaga","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0112","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijoa.2009.08.004","article-title":"The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage","volume":"19","author":"Bell","year":"2010","journal-title":"Int J Obstet Anesth"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0113","doi-asserted-by":"crossref","DOI":"10.1136\/tsaco-2016-000037","article-title":"Pre-emptive administration of fibrinogen concentrate contributes to improved prognosis in patients with severe trauma","volume":"1","author":"Yamamoto","year":"2016","journal-title":"Trauma Surg Acute Care Open"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0114","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12893-018-0398-z","article-title":"A systematic review on the use of topical hemostats in trauma and emergency surgery","volume":"18","author":"Chiara","year":"2018","journal-title":"BMC Surg"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0115","series-title":"StatPearls [Internet]","article-title":"Prothrombin Complex Concentrate","author":"Baskaran","year":"2020"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.07.006_bib0116","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11739-019-02177-2","article-title":"Reversal agents for oral anticoagulant-associated major or life-threatening bleeding","volume":"14","author":"Moia","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/21548331.2019.1643728","article-title":"Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists","volume":"47","author":"Desai","year":"2019","journal-title":"Hosp Pract (1995)"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0118","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/vox.12774","article-title":"Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis","volume":"114","author":"Hashmi","year":"2019","journal-title":"Vox Sanguin"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0119","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/000313481508100632","article-title":"Less is more: low-dose prothrombin complex concentrate effective in acute care surgery patients","volume":"81","author":"Quick","year":"2015","journal-title":"Am Surg"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tmrv.2013.01.002","article-title":"Use of prothrombin complex concentrates and fibrinogen concentrates in the perioperative setting: a systematic review","volume":"27","author":"Lin","year":"2013","journal-title":"Transfus Med Rev"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0121","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.amjsurg.2014.08.019","article-title":"Prothrombin complex concentrate in trauma patients","volume":"209","author":"Matsushima","year":"2015","journal-title":"Am J Surg"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0122","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/TA.0000000000001938","article-title":"The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: a propensity matched analysis","volume":"85","author":"Jehan","year":"2018","journal-title":"J Trauma Acute Care Surg"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0123","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/TA.0000000000002262","article-title":"Four-factor prothrombin complex concentrate is associated with improved survival in trauma-related hemorrhage: a nationwide propensity-matched analysis","volume":"87","author":"Zeeshan","year":"2019","journal-title":"J Trauma Acute Care Surg"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0124","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1055\/s-0039-3402024","article-title":"A case of acquired factor V deficiency in patient with bleeding","volume":"4","author":"Vetri","year":"2020","journal-title":"TH Open"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-0039-1687906","article-title":"A comprehensive overview of coagulation factor V and congenital factor V deficiency","volume":"45","author":"Tabibian","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0126","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/hae.13465","article-title":"\"In vitro\" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate","volume":"24","author":"Bulato","year":"2018","journal-title":"Haemophilia"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.07.006_bib0127","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/17474086.2016.1249364","article-title":"Diagnosis and management of factor V Leiden","volume":"9","author":"Campello","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0128","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s11095-016-1895-3","article-title":"Safety, stability and pharmacokinetic properties of (super)factor VA, a novel engineered coagulation factor V for treatment of severe bleeding","volume":"33","author":"Gale","year":"2016","journal-title":"Pharm Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/th15-07-0525","article-title":"Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superfactor VA and factor VIIA","volume":"115","author":"Bhat","year":"2016","journal-title":"Thromb Haemostas"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jth.12489","article-title":"Improved hemostasis in hemophilia mice by means of an engineered factor VA mutant","volume":"12","author":"von Drygalski","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.07.006_bib0131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104304","article-title":"An engineered factor VA prevents bleeding induced by anticoagulant WT activated protein C","volume":"9","author":"von Drygalski","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.07.006_bib0132","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIA in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0133","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13482","article-title":"Methodologies for data collection in congenital haemophilia with inhibitors (CHWI): critical assessment of the literature and lessons learned from recombinant factor VIIA","volume":"24","author":"Kessler","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0134","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-2000-8459","article-title":"Recombinant factor VIIA for the treatment of congenital factor VII deficiency","volume":"26","author":"Hunault","year":"2000","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/17474086.2014.980811","article-title":"Novoseven (recombinant factor viia) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia","volume":"7","author":"Franchini","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0136","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0035-1569068","article-title":"The judicious use of recombinant factor VIIA","volume":"42","author":"Goodnough","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0137","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MBC.0000000000000910","article-title":"In-vitro assessment of the effects of fibrinogen, recombinant factor VIIA and factor XIII on trauma-induced coagulopathy","volume":"31","author":"Budnik","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0138","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/CCM.0b013e31819fff2c","article-title":"A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIA in subjects with acute lung injury or acute respiratory distress syndrome","volume":"37","author":"Vincent","year":"2009","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0139","first-page":"63","article-title":"Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIA is more cost-effective than plasma","volume":"66","author":"Stein","year":"2009","journal-title":"J Trauma"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0140","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/cc6092","article-title":"Safety of RFVIIA in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial","volume":"11","author":"Kluger","year":"2007","journal-title":"Crit Care (Lond, Engl)"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0141","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/hae.12868","article-title":"Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single-centre experience of 19 years","volume":"22","author":"Ling","year":"2016","journal-title":"Haemophilia"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.07.006_bib0142","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1053\/j.jvca.2020.02.013","article-title":"Clot formation in cardiopulmonary bypass circuit after application of factor XI concentrate","volume":"34","author":"Hulsman","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0143","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/s-0036-1572324","article-title":"Clinical use of factor xiii concentrates","volume":"42","author":"Lassila","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0144","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-0030-1248726","article-title":"Von willebrand factor, adamts-13, and thrombotic thrombocytopenic purpura","volume":"36","author":"Zhou","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0145","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/asheducation-2013.1.292","article-title":"Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies","volume":"2013","author":"Crawley","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.07.006_bib0146","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jth.13341","article-title":"Preclinical assessment of a new recombinant adamts-13 drug product (bax930) for the treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Kopic","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.07.006_bib0147","first-page":"764","article-title":"Antithrombin III utilization in a large teaching hospital","volume":"38","author":"Salas","year":"2013","journal-title":"P T."},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0148","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/1076029609339748","article-title":"European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats","volume":"15","author":"Adiguzel","year":"2009","journal-title":"Clin Appl Thromb\/Hemostas"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0149","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood.V75.1.33.33","article-title":"Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative study group","volume":"75","author":"Menache","year":"1990","journal-title":"Blood."},{"issue":"3b","key":"10.1053\/j.seminhematol.2020.07.006_bib0150","doi-asserted-by":"crossref","first-page":"53s","DOI":"10.1016\/0002-9343(89)80533-9","article-title":"Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The antithrombin III study group","volume":"87","author":"Schwartz","year":"1989","journal-title":"Am J Med."},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0151","unstructured":"Thrombate III, prescribing information. Triangle park, NC: Grifols\/Talecris; 2009."},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0152","unstructured":"Atryn, prescribing information. Deerfield, IL: Ovation Pharmaceuticals, Inc.; 2009."},{"issue":"29","key":"10.1053\/j.seminhematol.2020.07.006_bib0153","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.3748\/wjg.v13.i29.3918","article-title":"Veno occlusive disease: update on clinical management","volume":"13","author":"Senzolo","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"7-8","key":"10.1053\/j.seminhematol.2020.07.006_bib0154","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1345\/aph.10220","article-title":"Prevention and treatment of veno-occlusive disease","volume":"35","author":"Pegram","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.07.006_bib0155","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1525-1594.2011.01384.x","article-title":"Antithrombin replacement during extracorporeal membrane oxygenation","volume":"35","author":"Niebler","year":"2011","journal-title":"Artif Organs"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.07.006_bib0156","first-page":"513","article-title":"Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience","volume":"52","author":"Agati","year":"2006","journal-title":"ASAIO J"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0157","first-page":"1687","article-title":"The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation\u2014a comparison with other anticoagulants","volume":"82","author":"Mohri","year":"1999","journal-title":"Thromb Haemostas"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0158","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13054-015-0810-3","article-title":"Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis","volume":"19","author":"Yoshimura","year":"2015","journal-title":"Crit Care (Lond, Engl)"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0159","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.12841","article-title":"Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis","volume":"13","author":"Yamakawa","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1160\/TH15-12-0987","article-title":"Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study","volume":"115","author":"Hayakawa","year":"2016","journal-title":"Thromb Haemostas."},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0161","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jth.12786","article-title":"Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study","volume":"13","author":"Tagami","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1053\/j.seminhematol.2020.07.006_bib0162","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2019.5358","article-title":"Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the scarlet randomized clinical trial","volume":"321","author":"Vincent","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0163","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21767\/2471-8505.100099","article-title":"The influence of human soluble recombinant thrombomodulin on in-hospital mortality in patients with acute respiratory distress syndrome and disseminated intravascular coagulation: a retrospective multicenter study","volume":"3","author":"Uba","year":"2017","journal-title":"J Intensive Crit Care"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0164","first-page":"51","article-title":"Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency","volume":"4","author":"Kroiss","year":"2010","journal-title":"Biologics"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.07.006_bib0165","first-page":"504","article-title":"An update on activated protein C (Xigris) in the management of sepsis","volume":"35","author":"Alaniz","year":"2010","journal-title":"P t."},{"issue":"9564","key":"10.1053\/j.seminhematol.2020.07.006_bib0166","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1053\/j.seminhematol.2020.07.006_bib0167","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death","volume":"353","author":"Abraham","year":"2005","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0168","doi-asserted-by":"crossref","first-page":"62","DOI":"10.22514\/SV81.052013.12","article-title":"Human protein C concentrate in a patient with meningitis and bleeding as a complication of treatment with recombinant activated protein C","volume":"8","author":"Colombo","year":"2013","journal-title":"Signa Vitae"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.07.006_bib0169","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14740\/jh478","article-title":"Protein S deficiency and arterial thromboembolism: a case report and review of the literature","volume":"8","author":"Fearon","year":"2019","journal-title":"J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0170","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/j.1365-2516.2008.01775.x","article-title":"Protein S deficiency: a clinical perspective","volume":"14","author":"ten Kate","year":"2008","journal-title":"Haemophilia"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0171","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1590\/abd1806-4841.20187310","article-title":"Warfarin-induced skin necrosis in a patient with protein s deficiency","volume":"93","author":"Fraga","year":"2018","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0172","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104608","article-title":"Ischemic stroke with protein s deficiency treated by apixaban","volume":"29","author":"Ohashi","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0173","article-title":"Rivaroxaban treatment for warfarin-refractory thrombosis in a patient with hereditary protein s deficiency","volume":"2018","author":"Ameku","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"1.2","key":"10.1053\/j.seminhematol.2020.07.006_bib0174","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2152\/jmi.66.182","article-title":"Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency","volume":"66","author":"Yagi","year":"2019","journal-title":"J Med Invest"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.07.006_bib0175","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1517\/14740338.2015.1094053","article-title":"The safety of treatments for angioedema with hereditary c1 inhibitor deficiency","volume":"14","author":"Zanichelli","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0176","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.iac.2017.04.003","article-title":"Prophylactic therapy for hereditary angioedema","volume":"37","author":"Longhurst","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0177","first-page":"92","article-title":"Fresh frozen plasma for the treatment of hereditary angioedema acute attacks","volume":"27","author":"Tang","year":"2012","journal-title":"Chin Med Sci J\u202f=\u202fChung-kuo i Hsueh k'o Hsueh tsa Chih"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0178","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1081-1206(10)60886-1","article-title":"Fresh frozen plasma for the treatment of hereditary angioedema","volume":"98","author":"Prematta","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.07.006_bib0179","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/pai.12444","article-title":"Safety and efficacy of c1 esterase inhibitor for acute attacks in children with hereditary angioedema","volume":"26","author":"Lumry","year":"2015","journal-title":"Pediatric Allergy Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.07.006_bib0180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/1744666X.2015.1012502","article-title":"Recombinant human c1 esterase inhibitor for the treatment of hereditary angioedema due to c1 inhibitor deficiency (c1-Inh-Hae)","volume":"11","author":"Sabharwal","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.07.006_bib0181","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12016-018-8684-1","article-title":"Update on the use of c1-esterase inhibitor replacement therapy in the acute and prophylactic treatment of hereditary angioedema","volume":"56","author":"Henry Li","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1053\/j.seminhematol.2020.07.006_bib0182","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.2147\/DDDT.S192475","article-title":"Lanadelumab injection treatment for the prevention of hereditary angioedema (HAE): design, development and place in therapy","volume":"13","author":"Bova","year":"2019","journal-title":"Drug Des Dev Therapy"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.07.006_bib0183","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1365-2516.2008.01766.x","article-title":"\u03912-antiplasmin and its deficiency: fibrinolysis out of balance","volume":"14","author":"Carpenter","year":"2008","journal-title":"Haemophilia"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.07.006_bib0184","first-page":"303","article-title":"Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal","volume":"2","author":"Lee","year":"2004","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632030024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632030024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:27:21Z","timestamp":1758522441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632030024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":184,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S003719632030024X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.07.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}